# Opna Bio: Oncology pharmaceutical company

> Company Opna Bio develops drugs targeting the Hallmarks of Cancer\.

Generated by Yoast SEO v28.4, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Team](https://www.opnabio.com/team/)
- [Pipeline](https://www.opnabio.com/pipeline/)
- [Terms Of Use](https://www.opnabio.com/terms-of-use/)
- [Press Releases](https://www.opnabio.com/press-releases/)
- [Patients](https://www.opnabio.com/patients/)

## Posts
- [Opna Bio Announces Fast Track Designation Granted to OPN\-6602 for the Treatment of Multiple Myeloma](https://www.opnabio.com/opna-bio-announces-fast-track-designation-granted-to-opn-6602-for-the-treatment-of-multiple-myeloma/): OPN\-6602 Currently Treating Patients in Phase 1 Clinical Trial
- [Opna Bio Showcases Multi\-Functional Degraders with Potent Anti\-Myeloma Activity and Encouraging Spleen Reductions in Patients with  Myelofibrosis Treated with OPN\-2853 and Ruxolitinib](https://www.opnabio.com/opna-bio-showcases-multi-functional-degraders-with-potent-anti-myeloma-activity-and-encouraging-spleen-reductions-in-patients-with-myelofibrosis-treated-with-opn-2853-and-ruxolitinib/): Data were shared at the 67th Annual Meeting of the American Society of Hematology \(ASH\)
- [Opna Bio Announces 2025 ASH Presentations Highlighting Preclinical Data from Novel Protein Degrader Program and Updated Interim Data from Phase 1 Combination Study of OPN\-2853 with Ruxolitinib in Advanced Myelofibrosis](https://www.opnabio.com/opna-bio-announces-2025-ash-presentations-highlighting-preclinical-data-from-novel-protein-degrader-program-and-updated-interim-data-from-phase-1-combination-study-of-opn-2853-with-ruxolitinib-in-adva/): Phase 1 Clinical Trial with OPN\-6602 in Multiple Myeloma Actively Enrolling Patients
- [Opna Bio Announces Orphan Drug Designation Granted to OPN\-2853 \(Zavabresib\) for the Treatment of Myelofibrosis](https://www.opnabio.com/opna-bio-announces-orphan-drug-designation-granted-to-opn-2853-zavabresib-for-the-treatment-of-myelofibrosis/)

## Team Members
- [Pan\-Yu Chen, PhD](https://www.opnabio.com/team-members/pan-yu-chen-phd/)
- [Bernice Matusow](https://www.opnabio.com/team-members/bernice-matusow/)
- [Kerry Inokuchi](https://www.opnabio.com/team-members/kerry-inokuchi/)
- [Axel Bolte](https://www.opnabio.com/team-members/axel-bolte/)
- [Somenath Chowdhury, PhD](https://www.opnabio.com/team-members/somenath-chowdhury-phd/)

## Programs
- [ZAVABRESIB](https://www.opnabio.com/programs/zavabresib/)
- [OPN\-FMRP](https://www.opnabio.com/programs/opn-fmrp/)
- [OPN\-9840](https://www.opnabio.com/programs/opn-tead/)
- [OPN\-9627](https://www.opnabio.com/programs/opn-9627/)
- [OPN\-7486](https://www.opnabio.com/programs/opn-7486/)

## Location
- [South San Francisco, CA](https://www.opnabio.com/location/south-san-francisco-ca-2/)
- [San Diego, CA](https://www.opnabio.com/location/san-diego-ca/)
- [Lausanne](https://www.opnabio.com/location/lausanne/)
- [Switzerland](https://www.opnabio.com/location/switzerland/)
- [Orlando, FL](https://www.opnabio.com/location/orlando-fl/)

## Type
- [Publication](https://www.opnabio.com/publication-type/publication/)
- [Poster](https://www.opnabio.com/publication-type/poster/)
- [Presentation](https://www.opnabio.com/publication-type/presentation/)
- [Oral Presentation](https://www.opnabio.com/publication-type/oral-presentation/)

## Program
- [OPN\-51107](https://www.opnabio.com/publication-program/opn-51107/)
- [Zavabresib \(OPN\-2853\)](https://www.opnabio.com/publication-program/opn-2853/)
- [OPN\-7486](https://www.opnabio.com/publication-program/opn-7486/)
- [OPN\-6602](https://www.opnabio.com/publication-program/opn-6602/)
- [OPN\-TEAD](https://www.opnabio.com/publication-program/opn-tead/)

## Optional
- [Sitemap index](https://www.opnabio.com/sitemap_index.xml)